Latest

Why Halozyme Therapeutics is the Biotech Stock to Watch Now

Why Halozyme Therapeutics is the Biotech Stock to Watch Now

February 12, 2025
Biotech stocks are volatile, influenced by FDA trial outcomes and therapy demand. Halozyme Therapeutics shines with its Enhaze platform, enabling subcutaneous drug delivery using the rHuPH20 enzyme. This technology improves drug absorption and patient comfort, offering a competitive advantage. In Q3 2024,
1 269 270 271 272 273 608